Table 5.
Multivariate Cox regression analysis for hepatocellular carcinoma and death/transplantation among the sustained virologic response cohort
|
Variable
|
Hepatocellular carcinoma
|
Death/transplantation
|
||
|
aHR (95%CI)
|
P
value
|
aHR (95%CI)
|
P
value
|
|
| IBT-SVR group | Reference | - | Reference | - |
| DAA-SVR group | 2.03 (0.76-5.43) | 0.16 | 1.38 (0.55-3.49) | 0.494 |
| Age, yr | 1.05 (1.01-1.10) | 0.025 | - | - |
| Male sex | 2.89 (0.97-8.61) | 0.057 | - | - |
| HCV genotype | - | – | ||
| 2 | Reference | - | ||
| 1 | 3.02 (1.18-7.68) | 0.021 | ||
| Cirrhosis | 3.18 (1.33-7.68) | 0.009 | 2.97 (1.42-6.20) | 0.004 |
| Ever smoker | 0.72 (0.26-1.99) | 0.545 | - | - |
| Alcohol consumption | - | - | ||
| None | Reference | - | ||
| Social | 2.62 (0.92-7.60) | 0.072 | ||
| Significant | 2.51 (0.71-8.82) | 0.152 | ||
| BMI, kg/m2 | - | - | - | - |
| Diabetes mellitus | 1.03 (0.42-2.52) | 0.952 | 2.16 (0.98-4.78) | 0.057 |
| Albumin, g/dL | 0.53 (0.19-1.49) | 0.228 | - | - |
| Total bilirubin, mg/dL | - | - | - | - |
| PT, INR | 4.12 (0.89-19.17) | 0.071 | 5.27 (1.01-27.53) | 0.049 |
| AFP, log10 ng/dL | 1.07 (0.49-2.34) | 0.858 | - | - |
Total number of patients, 1250; number of hepatocellular carcinomas, 30; number of deaths, 7; number of transplantations, 3. AFP: Alpha-feto protein; aHR: Adjusted hazard ratio; BMI: Body mass index; CI: Confidence interval; DAA: Direct acting antivirals; HCV: Hepatitis C virus; IBT: Interferon-based therapy; PT: Prothrombin time; SVR: Sustained virologic response.